CRYOPORT, INC. Unusual or Infrequent Item, or Both, Insurance Proceeds
CRYOPORT, INC. (CYRX) reported Unusual or Infrequent Item, or Both, Insurance Proceeds of $15.10 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-07.
Financial Statements › Notes › Unusual or Infrequent Item, or Both, Net of Insurance Proceeds
us-gaap:UnusualOrInfrequentItemInsuranceProceeds · last filed 2025-03-07
- CRYOPORT, INC. unusual or infrequent item, or both, insurance proceeds for the quarter ending 2023-03-31 was $2.20M.
- CRYOPORT, INC. unusual or infrequent item, or both, insurance proceeds for fiscal 2024 was $15.10M.
| Period end | Unusual or Infrequent Item, or Both, Insurance Proceeds | Unusual or Infrequent Item, or Both, Insurance Proceeds 3 month | Unusual or Infrequent Item, or Both, Insurance Proceeds 12 month |
|---|---|---|---|
| 2024-12-31 | $15.10M 10-K · filed 2025-03-07 | ||
| 2024-01-25 | $15.10M 10-Q · filed 2024-11-07 | ||
| 2023-03-31 | $2.20M 10-K · filed 2025-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |